Everest Medicines, AbCellera ink multiyear deal

By The Science Advisory Board staff writers

September 23, 2021 -- Everest Medicines and AbCellera have entered into a multiyear collaboration and license agreement to discover therapeutic antibodies for up to 10 targets that will be selected by Everest. The initial programs will focus on targets in oncology, Everest said.

Under the agreement, Everest will leverage AbCellera's technology, including sourcing fully humanized antibodies from the Trianni mouse, sourcing single-domain antibodies from camelids, and combining antibodies to create native bispecifics using the OrthoMab protein engineering platform.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.